Drug Shortage Report for TEVA-ABACAVIR/LAMIVUDINE
| Report ID | 249179 |
| Drug Identification Number | 02416662 |
| Brand name | TEVA-ABACAVIR/LAMIVUDINE |
| Common or Proper name | ABACAVIR/LAMIVUDINE 600/300MG |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | LAMIVUDINE ABACAVIR |
| Strength(s) | 300MG 600MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | ALL |
| ATC code | J05AR |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2025-01-29 |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-01-30 |
| Company comments | Susp Supply |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-01-30 | French | Compare |
| v1 | 2025-01-30 | English | Compare |
Showing 1 to 2 of 2